Gamboa Nicholas T, Joyce Evan J, Eli Ilyas, Park Min S, Taussky Philipp, Schmidt Richard H, McDonald Jamie, Whitehead Kevin J, Kalani M Yashar S
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah School of Medicine, Salt Lake City, UT, United States.
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah School of Medicine, Salt Lake City, UT, United States; University of Utah Hereditary Hemorrhagic Telangiectasia Center of Excellence, Salt Lake City, UT, United States.
J Clin Neurosci. 2018 May;51:22-28. doi: 10.1016/j.jocn.2018.01.019. Epub 2018 Feb 23.
Hereditary hemorrhagic telangiectasia (HHT) is characterized by recurrent spontaneous epistaxis, mucocutaneous telangiectases, and multisystem arteriovenous malformations (AVMs). Brain AVMs typically present at birth and are identified in approximately 10-20% of patients with HHT. A retrospective review was undertaken of all HHT patients with known single or multiple brain AVMs treated at our institution. Thirty-nine patients with brain AVM(s) were diagnosed with HHT. Most patients presented with at least one Curaçao criterion. A total of 78 brain AVMs were identified in 39 patients. Two-thirds of patients had solitary brain AVMs, whereas 33% of patients harbored at least two lesions (range: 2-16). Brain AVMs of the supratentorial cerebral hemispheres comprised 83% of all lesions, whereas infratentorial lesions accounted for only 17%. Of the 55 brain AVMs assigned Spetzler-Martin grading, the majority of patients were Grade 1 (73%), and 23% and 4% were Grades 2 and 3, respectively. Patients were treated with surgery alone (51%), embolization alone (6%), embolization followed by surgery (9%), stereotactic radiosurgery (11%), stereotactic radiosurgery followed by surgery (3%), or observation (20%). Of patients who underwent genetic analysis, 62% possessed mutations in ENG (HHT type 1), whereas 38% had mutations in ACVRL1 (HHT type 2). This robust patient cohort of brain AVMs in 39 patients with HHT advances the collective understanding of this disease's varied presentation, diagnostic workup, genetic underpinnings, and available treatment options.
遗传性出血性毛细血管扩张症(HHT)的特征为反复自发性鼻出血、黏膜皮肤毛细血管扩张以及多系统动静脉畸形(AVM)。脑动静脉畸形通常在出生时就存在,在约10%-20%的HHT患者中可被发现。我们对本机构治疗的所有已知患有单发或多发脑动静脉畸形的HHT患者进行了一项回顾性研究。39例患有脑动静脉畸形的患者被诊断为HHT。大多数患者至少符合一项库拉索标准。39例患者共发现78处脑动静脉畸形。三分之二的患者有单发脑动静脉畸形,而33%的患者至少有两处病变(范围:2-16处)。幕上大脑半球的脑动静脉畸形占所有病变的83%,而幕下病变仅占17%。在55处接受斯佩茨勒-马丁分级的脑动静脉畸形中,大多数患者为1级(73%),2级和3级分别占23%和4%。患者接受的治疗方式包括单纯手术(51%)、单纯栓塞(6%)、栓塞后手术(9%)、立体定向放射外科手术(11%)、立体定向放射外科手术后手术(3%)或观察(20%)。在接受基因分析的患者中,62%携带ENG基因突变(HHT 1型),而38%携带ACVRL1基因突变(HHT 2型)。这一由39例患有脑动静脉畸形的HHT患者组成的强大队列,增进了我们对该疾病多样表现、诊断检查、遗传基础及可用治疗方案的总体认识。